Amid Ongoing Payor Discussions, Clinical Trials, Biodesix Helps Patients Pay for Predictive Lung Cancer Dx
December 02, 2009
Amid Ongoing Payor Discussions, Clinical Trials, Biodesix Helps Patients Pay for Predictive Lung Cancer Dx
Biodesix offers to help pay for the cost of the test for those patients whose doctors have determined they need it, but who don't have adequate insurance coverage.
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- Biodesix Publishes Study Indicating Significant Influence of Veristrat on Doctor Treatment Decisions
April 5, 2013 / ProteoMonitor - Biodesix IDs Proteomic Signature for Predicting Response to GlobeImmune Pancreatic Cancer Therapy
June 29, 2012 / ProteoMonitor - Biodesix Study Investigates Use of Veristrat with Novartis, GSK Breast Cancer Drugs
December 16, 2011 / ProteoMonitor - Biodesix Inks Deal with Bruker for Mass Spec Support; Closes on $8.8M in Series D Financing
April 11, 2013 / GenomeWeb Daily News - Study Suggests Biodesix's Veristrat Can Identify NSCLC Responders to Erlotinib, Gemcitabine
September 7, 2012 / ProteoMonitor